Back to list

Rita Scarpelli


Research Line

D3 Validation


Via Morego, 30
+39 010 71781 233


Rita Scarpelli was educated at the University of Rome ‘La Sapienza’ (Italy) where she graduated in Chemistry in 1995. She received her Ph.D. in Organic Chemistry from the same Institution in 1998, under the supervision of Professor R. Marini Bettolo, working on the development of new and simplified synthetic strategies of different classes of polycyclic diterpenes.

In Feb. 1999, Dr Scarpelli joined the group of Professor K.C. Nicolaou at The Scripps Research Institute (TSRI), La Jolla, CA (USA) as Postdoctoral Research Associate. Her project was focused on the synthesis and biological evaluation of Epothilone B analogues.

After this experience, she moved to the University of Rome ‘Tor Vergata’ where she became Researcher (C06X) at the Department of Chemical Science and Technologies in the group of Professor B. Crociani. During that period, Dr Scarpelli worked on the design, preparation and studies of the catalytic applications of Pd complexes containing iminophosphine ligands.

In Feb. 2001, Dr Scarpelli joined the Medicinal Chemistry Department of Merck Sharp & Dohme (IRBM, MRL-Rome) as Senior Research Chemist, where she worked on different drug discovery programs, mainly in the antiviral (e.g., HIV-Integrase inhibitors) and antitumoral research fields (e.g., histone deacetylase (HDAC) inhibitors, poly(ADP-ribose)polymerase (PARP) inhibitors). During that period, Dr Scarpelli was part of the group which discovered Isentress®, first-in-class oral HIV Integrase inhibitor. She played also a crucial role in the discovery of different other drugs currently in clinical trial development.

Dr Scarpelli joined the Italian Institute of Technology (IIT) in November 2009, where she currently holds a Team Leader position in the Drug Discovery and Development Unit (D3) working on different research programs.

Her research has resulted in 19 patent applications and 42 papers in leading international journals.



Selected Publications


1) Kernel-Based, Partial Least Squares Quantitative Structure-Retention Relationship Model for UPLC Retention Time Prediction: A Useful Tool for Metabolite Identification. Falchi F., Bertozzi Mandrup S., Ottonello G., Ruda G.F., Colombano G., Fiorelli C., Martucci C., Bertorelli R., Scarpelli R., Cavalli A., Bandiera T., Armirotti A. Analytical Chemistry, 2016, 88(19), 9510-9517.

2) Second-generation non-covalent NAAA inhibitors are protective in model of multiple sclerosis. Migliore M., Pontis S., Fuentes de Arriba A. L., Realini N., Torrente E., Armirotti A., Romeo E., Di Martino S., Russo D., Pizzirani D., Summa M., Lanfranco M., Ottonello G., Busquet P., Jung K.-M., Garcia-Guzman M., Heim R., Scarpelli R.,* Piomelli D. Angew. Chem. Int. Ed., 2016, 55(37), 11193 –11197. Classified as Hot Paper by Angew. Chem. Int. Ed. referees.

3) Potent multitarget FAAH-COX inhibitors: Design and structure-activity relationship studies, Migliore, M., Habrant, D., Sasso, O., Albani, C., Bertozzi, Mandrup S., Armirotti, A., Piomelli, D., Scarpelli, R.*. Eur. J. Med. Chem. 2016, 109, 216-237.

4) Fluorine nuclear magnetic resonance-based assay in living mammalian cells. Veronesi, M., Giacomina, F., Romeo, E., Castellani, B., Ottonello, G., Lambruschini, C., Garau, G., Scarpelli, R., Bandiera, T., Piomelli, D. Dalvit, C., Analytical Biochemistry, 2016, 495, 52-59.

5) Benzoxazolone Carboxamides as Potent Acid Ceramidase Inhibitors: Synthesis and Structure-Activity Relationship (SAR) Studies. Bach, A., Pizzirani, D., Realini, N., Vozella, V., Russo, D., Penna, I., Melzig, L., Scarpelli, R., Piomelli, D. J. Med. Chem., 2015, 58(23), 9258-9272.

6) A Double Whammy: Targeting Both Fatty Acid Amide Hydrolase (FAAH) and Cyclooxygenase (COX) To Treat Pain and Inflammation. Scarpelli, R., Sasso, O., Piomelli, D., ChemMedChem 2016, 11(12), 1242-1251.

7) Multitarget fatty acid amide hydrolase/cyclooxygenase blockade suppresses intestinal inflammation and protects against nonsteroidal anti-inflammatory drug-dependent gastrointestinal damage. Sasso, O., Migliore, M., Habrant, D., Armirotti, A., Albani, C., Summa, M., Moreno-Sanz, G., Scarpelli, R., Piomelli, D. FASEB Journal, 2015, 29(6), 2616-2627.

8) 3,4-Dihydro-1,3,5-triazin-2(1H)-ones as the First Dual BACE-1/GSK-3b Fragment Hits against Alzheimer's Disease. Prati, F., De Simone, A., Armirotti, A., Summa, M., Pizzirani, D., Scarpelli, R., Bertozzi Mandrup S., Perez, D. I., Andrisano, V., Perez-Castillo, A. et al. ACS Chemical Neuroscience, 2015, 6, (10), 1665-1682.

9) Synthesis and in Vitro Anticancer Activity of the First Class of Dual Inhibitors of REV-ERBb and Autophagy. Torrente, E., Parodi, C., Ercolani, L., De Mei, C., Ferrari, A., Scarpelli, R.,* Grimaldi, B. J. Med. Chem., 2015, 58(15), 5900-5915.

10) O-(Triazolyl)methyl Carbamates as a Novel and Potent Class of Fatty Acid Amide Hydrolase (FAAH) Inhibitors. Colombano, G., Albani, C., Ottonello, G., Ribeiro, A., Scarpelli, R., Tarozzo, G., Daglian, J., Jung, K.-M., Piomelli, D., Bandiera,T. ChemMedChem., 2015, 10(2), 380-395.

11) Multitarget Drug Discovery for Alzheimer's Disease: Triazinones as BACE-1 and GSK-3b Inhibitors. Prati, F., De Simone, A., Bisignano, P., Armirotti, A., Summa, M. Pizzirani, D., Scarpelli, R., Perez, D. I.; Andrisano, V., Perez-Castillo, A., et al. Angew. Chem. Int. Ed., 2015, 54(5), 1578-1582.

12) Dual inhibition of REV-ERBβ and autophagy as a novel pharmacological approach to induce cytotoxicity in cancer cells. De Mei C., Ercolani L., Parodi C., Veronesi M., Lo Vecchio C., Bottegoni G., Torrente E., Scarpelli R., Marotta R., Ruffili R., Wade M., Mattioli M., Reggiani A., Grimaldi B. Oncogene, 2015, 34(20), 2597-2608.

13) Structural determinants of peripheral O-arylcarbamate FAAH inhibitors render them dual substrates for Abcb1 and Abcg2 and restrict their access to the brain. Moreno-Sanz G., Barrera B., Armirotti A., Bertozzi Mandrup S., Scarpelli R., Bandiera T., Prieto J. G., Duranti A., Tarzia G., Merino G., Piomelli D. Pharmacol. Res. 2014, 87, 87–93.

14) Fluorine NMR-Based Screening on Cell Membrane Extracts. Veronesi, M. Romeo, E. Lambruschini, C. Piomelli, D. Bandiera, T. Scarpelli, R. Garau, G. Dalvit, C. ChemMedChem, 2014, 9(2), 286-289.

15) Development of Fragment-Based n-FABS NMR Screening Applied to the Membrane Enzyme FAAH. Lambruschini C., Veronesi M., Romeo E., Garau, G., Bandiera T., Piomelli D., Scarpelli R., Dalvit C. ChemBioChem, 2013, 14(13), 1611-1619. Classified as very important paper (VIP) by ChemBioChem referees.

16) Synthesis and Structure-Activity Relationship Studies of O-Biphenyl-3-yl Carbamates as Peripherally Restricted Fatty Acid Amide Hydrolase Inhibitors. Moreno-Sanz G., Duranti A., Melzig L., Fiorelli, C., Ruda G. F., Colombano G., Mestichelli P., Sanchini S., Tontini A., Mor M., Bandiera T., Scarpelli R., Tarzia G., Piomelli D. J. Med. Chem., 2013, 56(14), 5917-5930.

17) Discovery of a New Class of Highly Potent Inhibitors of Acid Ceramidase: Synthesis and Structure-Activity Relationship (SAR). Pizzirani, D., Pagliuca, C., Realini, N., Branduardi, D., Bottegoni, G., Mor M., Bertozzi, F., Scarpelli, R., Piomelli, D., Bandiera, T. J. Med. Chem., 2013, 56(9), 3518-3530.

18) Development of a multigram synthesis of URB937, a peripherally restricted FAAH inhibitor. Fiorelli, C., Scarpelli, R., Piomelli, D., Bandiera, T. Org. Process Res. Dev. 2013, 17(3), 359−367.

19) A binding site for non-steroidal anti-inflammatory drugs in Fatty Acid Amide Hydrolase. Bertolacci L., Romeo E., Veronesi M., Magotti P., Albani C., Dionisi M., Lambruschini C., Scarpelli R., Cavalli A., De Vivo M., Piomelli D., Garau G. J. Am. Chem. Soc., 2013, 135(1), 22-25.

20) Identification of carprofen and its derivatives as multi-target FAAH/COX inhibitors. Favia A. D., Habrant D., Scarpelli R., Migliore M., Albani C., Bertozzi Mandrup S., Dionisi M., Tarozzo G., Piomelli D., Cavalli A., De Vivo M. J. Med. Chem., 2012, 55(20), 8807-8826.

21) Peripheral FAAH inhibition causes profound antinociception and protects against indomethacin-induced gastric lesions. Sasso O., Bertorelli R., Bandiera T., Scarpelli R., Colombano G., Armirotti A., Moreno-Sanza G., Reggiani A., Piomelli D. Pharmacol. Res. 2012, 65(5), 553-563.

22) Identification of MK-5710 ((8aS)-8a-methyl-1,3-dioxo-2-[(1S,2R)-2-phenylcyclopropyl]-N-(1-phenyl-1H-pyrazol-5-yl)hexahydroimid azo[1,5-a]pyrazine-7(1H)-carboxamide), a potent smoothened antagonist for use in Hedgehog pathway dependent malignancies, Part 2. Kinzel O., Alfieri A., Altamura S., Brunetti M., Bufali S., Colaceci F., Ferrigno F., Filocamo G., Fonsi M., Gallinari P., Malancona S., Martin Hernando J. I., Monteagudo E., Orsale M. V., Palumbi M. C., Pucci V., Rowley M., Sasso R., Scarpelli R., Steinkühler C., Jones P. Bioorg. Med. Chem. Lett., 2011, 21(15), 4429-4435.

23) Identification of MK-5710 ((8aS)-8a-methyl-1,3-dioxo-2-[(1S,2R)-2-phenylcyclopropyl]-N-(1-phenyl-1H-pyrazol-5-yl)hexahydroimid azo[1,5-a]pyrazine-7(1H)-carboxamide), a potent smoothened antagonist for use in Hedgehog pathway dependent malignancies, Part 1. Malancona S., Altamura S., Filocamo G., Kinzel O., Martin Hernando J. I., Rowley M., Scarpelli R., Steinkühler C., Jones P. Bioorg. Med. Chem. Lett., 2011, 21(15), 4422-4428.

24) Synthesis and biological evaluation of substituted 2-phenyl-2H-indazole-7-carboxamides as potent poly(ADP-ribose)polymerase (PARP) inhibitors. Scarpelli, R., Boueres, J. K., Cerretani, M., Ferrigno, F., Ontoria, J. M., Rowley, M., Schultz-Fademrecht, C., Toniatti, C., Jones, P. Bioorg. Med. Chem. Lett., 2010, 20(2), 488-492.

25) Discovery of 2-{4-[(3S)-Piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): A Novel Oral Poly(ADP-ribose)polymerase (PARP) Inhibitor Efficacious in BRCA-1 and -2 Mutant Tumors. Jones P., Altamura S., Boueres J. K., Ferrigno F., Fonsi M., Giomini C., Lamartina S., Monteagudo E., Ontoria J. M., Orsale M. V., Palumbi M. C., Pesci S., Roscilli G., Scarpelli R., Schultz-Fademrecht C., Toniatti C., Rowley M. J. Med. Chem., 2009, 52(22), 7170-7185.

26) Identification of Novel, Selective, and Stable Inhibitors of Class II Histone Deacetylases: Validation Studies of the Inhibition of the Enzymatic Activity of HDAC4 by Small Molecules as a Novel Approach for Cancer Therapy. Ontoria J. M., Altamura S., Di Marco A., Ferrigno F., Laufer R., Muraglia E., Palumbi M. C., Rowley M., Scarpelli R., Schultz-Fademrecht C., Serafini S., Steinkühler C., Jones P. J. Med. Chem., 2009, 52(21), 6782-6789.

27) 2-Trifluoroacetylthiophene oxadiazoles as potent and selective class II human histone deacetylase inhibitors. Muraglia E., Altamura S., Branca D., Cecchetti O., Ferrigno F., Orsale M. V., Palumbi M. C., Rowley M., Scarpelli R., Steinkühler C., Jones P. Bioorg. Med. Chem. Lett., 2008, 18(23), 6083-6087.

28) Studies of the metabolic stability in cells of 5-(trifluoroacetyl)thiophene-2-carboxamides and identification of more stable class II histone deacetylase (HDAC) inhibitors. Scarpelli R., Di Marco A., Ferrigno F., Laufer R., Marcucci I., Muraglia E., Ontoria J. M., Rowley M., Serafini S., Steinkühler C., Jones P. Bioorg. Med. Chem. Lett., 2008, 18(23), 6078-6082.

29) Structural and functional analysis of the human HDAC4 catalytic domain reveals a regulatory structural zinc-binding domain. Bottomley M. J., Lo Surdo P., Di Giovine P., Cirillo A., Scarpelli R., Ferrigno F., Jones P., Neddermann P., De Francesco R., Steinkühler C., Gallinari P., Carfí. A. J. Biol. Chem., 2008, 283(39), 26694-26704.

30) Discovery of Raltegravir, a potent, selective orally bioavailable HIV-Integrase inhibitor for the treatment of HIV-AIDS infection. Summa, V., Petrocchi, A., Bonelli, F., Crescenzi, B., Donghi, M., Ferrara, M., Fiore, F., Gardelli, C., Gonzalez Paz, O., Hazuda, D. J., Jones, P., Kinzel, O., Laufer, R., Monteagudo, E., Muraglia, E., Nizi, E., Orvieto, F., Pace, P., Pescatore, G., Scarpelli, R., Stillmock, K., Witmer, M. V., Rowley, M. J. Med. Chem., 2008, 51, 5843-5855.

31) 2-Trifluoroacetylthiophenes, a novel series of potent and selective class II histone deacetylase inhibitors. Jones, P., Bottomley, M. J., Carfi, A., Cecchetti, O., Ferrigno, F., Lo Surdo, P., Ontoria, J. M., Rowley, M., Scarpelli, R., Schultz-Fademrecht, C., Steinkühler, C. Bioorg. Med. Chem. Lett., 2008, 18(11), 3456-3461.

32) Discovery and synthesis of HIV Integrase inhibitors: development of potent and orally bioavailable N-Methyl Pyrimidones. Gardelli, C., Nizi, E., Muraglia, E., Crescenzi, B., Ferrara, M., Orvieto, F., Pace, P., Pescatore, G., Poma, M., Rico Ferreira, M., Scarpelli, R., Homnick, C. F., Ikemoto, N., Alfieri, A., Verdirame, M., Bonelli, F., Gonzalez Paz, O., Taliani, M., Monteagudo, E., Pesci, S., Laufer, R., Felock, P., Stillmock, K. A., Hazuda, D., Rowley, M., Summa, V. J. Med. Chem., 2007, 50(20), 4953-4975.

33) Dihydroxypyrimidine-4-carboxamides as novel potent and selective HIV Integrase inhibitors. Pace, P., Di Francesco, M. E., Gardelli, C., Harper, S., Muraglia, E., Nizi, E., Orvieto, F., Petrocchi, A., Poma, M., Rowley, M., Scarpelli, R., Laufer, R., Gonzalez Paz, O., Monteagudo, E., Bonelli, F., Hazuda, D., Stillmock, K.A., Summa, V. J. Med. Chem., 2007, 50(9), 2225-2239.

34) A series of novel, potent, and selective histone deacetylase inhibitors. Jones, P., Altamura, S., Chakravarty, P. K., Cecchetti, O., De Francesco, R., Gallinari, P., Ingenito, R., Meinke, P. T., Petrocchi, A., Rowley, M., Scarpelli, R., Serafini, S., Steinkuehler, C. Bioorg. Med. Chem. Lett., 2006, 16(23), 5948-5952.

35) Iminophosphine-palladium (0) complexes as catalysts in the alkoxycarbonylation of terminal alkynes. Scrivanti, A., Matteoli, U., Beghetto, V., Antonaroli, S., Scarpelli, R., Crociani B. J. Mol. Catal. A: Chem., 2001, 170, 51-56.

36) Chemical synthesis and biological properties of Pyridine Epothilones. Nicolaou, K.C., Scarpelli, R., Bollbuck, B., Werschkun, B., Pereira, M. M. A., Wartmann, M., Altmann, K-H., Zaharevitz, D., Gussio, R., Giannakakou, P. Chemistry & Biology, 2000, 7(8), 593-599.

37) Total synthesis of 16-Desmethylepothilone B, Epothilone B10, Epothilone F and related side-chain modified Epothilone B Analogues. Nicolaou, K.C., Hepworth, D., King, N. P., Finlay, M. R. V., Scarpelli, R., Pereira, M. M. A., Bollbuck, B., Bigot, A., Werschkun, B., Winssinger, N. Chem. Eur. J., 2000, 6(15), 2783-2800.

38) Improved conversion of 6-endo-tosyloxybicyclo[2.2.2]octan-2-ones into 6-exo-Acetoxy and 6-exo-Benzoyloxybicyclo[2.2.2]octan-2-ones. Marini Bettolo, R., Migneco, L. M., Moretti, P., Scarpelli, R. J. Prakt. Chem., 1999, 341(7), 687-690.

39) On the diastereoselectivity of the aqueous-acid-catalyzed intramolecular aldol condensation of 3-Oxocyclohexaneacetaldehydes. De Santis, B., Iamiceli, A. L., Marini Bettolo, R., Migneco, L. M., Scarpelli, R., Cerichelli, G., Fabrizi, G., Lamba, D. Helv. Chim. Acta, 1998, 81(12), 2375-2387.

40) Unprecedented Grob-type fragmentation of 5-dioxolan-bicyclo[4.2.0]octan-2-ones into 3-(methoxycarbonylmethyl)-cyclohaxanones. De Giacomo, M., Marini Bettolo, R., Scarpelli R. Tetrahedron Lett., 1997, 38(19), 3469-3470.

41) A formal total synthesis of (+)-Methyl Trachyloban-18-oate and (+)-Methyl 16-Oxo-17-Norkauran-18-oate: regio and diastereoselective preparation of Methyl (13S)-13-Hydroxyisoatisiren-18-oate from (-)-Abietic Acid. Berettoni, M., De Chiara, G., Iacoangeli, T., Lo Surdo, P., Marini Bettolo, R., Montagnini di Mirabello, L., Nicolini L., Scarpelli. R. Helv. Chim. Acta, 1996, 79(7), 2035-2041.

42) Studies for a diastereoselective synthesis of the tetracyclic diterpenic diol stemarin. A model work for the preparation, from an 8(9)-podocarpen-14-one, of a key intermediate by the Wiesner photochemical method. Bartoletti, A., Berettoni, M., Catteruccia, F., De Chiara, G., Lamba, D., Marini Bettolo, R., Mastrangeli, C., Scarpelli, R., Tozzi C. Gazz. Chim. Ital., 1996, 126(4), 223-226. 




1) Preparation of novel triazinones as dual inhibitor compounds for use in the treatment of neurodegenerative disorders and Alzheimer's disease. WO189830 (2015). 

2) Substituted benzoxazolone derivatives as acid ceramidase inhibitors, and their use as medicaments. WO173169 (2015).

3) Preparation of cycloalkylcarbamate compounds as inhibitors of fatty acid amide hydrolase (FAAH) enzyme with improved oral bioavailability. WO157313 (2015).

4) Diarylalkylamine derivatives as rev-erb antagonists and their preparation and use for the treatment of cancer. WO052283 (2015). 

5) Multitarget FAAH and COX inhibitors and therapeutical uses thereof. WO023643 (2014).

6) Preparation of 3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinecarboxamide compounds as acid ceramidase inhibitors and their use as medicaments. WO178545 (2013).

7) Preparation of 3,4-dihydro-1(2H)-pyrimidinecarboxamide compounds as acid ceramidase inhibitors and their use as medicaments. WO178576 (2013).

8) Saturated bicyclic heterocyclic derivatives as Smoothened (SMO) antagonist. WO023480 (2010).

9) Tricyclic derivatives as inhibitors of poly(ADP-ribose)polymerase (PARP). WO112832 (2009).

10) Quinolin-4-one and 4-oxodihydrocinnoline derivatives as inhibitors of poly(ADP-ribose)polymerase (PARP). WO027730 (2009).

11) Preparation of piperidinylphenylindazolylcarboxamide for use as poly(ADP-ribose)polymerase inhibitors. WO084261 (2008).

12) 4-oxo-4,5-dihydropyrrolo[1,2-a] quinoxaline derivatives as inhibitors of poly(ADP-ribose)polymerase (PARP). WO017883 (2008).

13) Thiophene and thiazole substituted trifluoroethanone derivatives as histone deacetylase (HDAC) inhibitors. WO029035 (2007).

14) Heterocyclylalkyl ketones as histone deacetylase (HDAC) inhibitors. WO072080 (2007).

15) Thiophene and thiazole substituted trifluoroethanone derivatives as histone deacetylase (HDAC) inhibitors. WO093827 (2007).

16) Amide substituted indazole and benzotriazole derivatives as poly (ADP-ribose)polymerase (PARP) inhibitors. WO113596 (2007).

17) Heterocycle derivatives as histone deacetylase (HDAC) inhibitors. WO061638 (2006).

18) Amino acid amide derivatives as inhibitors of histone deacetylase. WO005941 (2006).

19) N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase. WO035077 (2003).


IIT's website uses the following types of cookies: browsing/session, analytics, functional and third party cookies. Users can choose whether or not to accept the use of cookies and access the website. By clicking on "Further Information", the full information notice on the types of cookies will be displayed and you will be able to choose whether or not to accept them whilst browsing on the website
Further Information
Accept and close

I numeri di IIT

L’Istituto Italiano di Tecnologia (IIT) è una fondazione di diritto privato - cfr. determinazione Corte dei Conti 23/2015 “IIT è una fondazione da inquadrare fra gli organismi di diritto pubblico con la scelta di un modello di organizzazione di diritto privato per rispondere all’esigenza di assicurare procedure più snelle nella selezione non solo nell’ambito nazionale dei collaboratori, scienziati e ricercatori ”.

IIT è sotto la vigilanza del Ministero dell'Istruzione, dell'Università e della Ricerca e del Ministero dell'Economia e delle Finanze ed è stato istituito con la Legge 326/2003. La Fondazione ha l'obiettivo di promuovere l'eccellenza nella ricerca di base e in quella applicata e di favorire lo sviluppo del sistema economico nazionale. La costruzione dei laboratori iniziata nel 2006 si è conclusa nel 2009.

Lo staff complessivo di IIT conta circa 1440 persone. L’area scientifica è rappresentata da circa l’85% del personale. Il 45% dei ricercatori proviene dall’estero: di questi, il 29% è costituito da stranieri provenienti da oltre 50 Paesi e il 16% da italiani rientrati. Oggi il personale scientifico è composto da circa 60 principal investigators, circa 110 ricercatori e tecnologi di staff, circa 350 post doc, circa 500 studenti di dottorato e borsisti, circa 130 tecnici. Oltre 330 posti su 1400 creati su fondi esterni. Età media 34 anni. 41% donne / 59 % uomini.

Nel 2015 IIT ha ricevuto finanziamenti pubblici per circa 96 milioni di euro (80% del budget), conseguendo fondi esterni per 22 milioni di euro (20% budget) provenienti da 18 progetti europei17 finanziamenti da istituzioni nazionali e internazionali, circa 60 progetti industriali

La produzione di IIT ad oggi vanta circa 6990 pubblicazioni, oltre 130 finanziamenti Europei e 11 ERC, più di 350 domande di brevetto attive, oltre 12 start up costituite e altrettante in fase di lancio. Dal 2009 l’attività scientifica è stata ulteriormente rafforzata con la creazione di dieci centri di ricerca nel territorio nazionale (a Torino, Milano, Trento, Parma, Roma, Pisa, Napoli, Lecce, Ferrara) e internazionale (MIT ed Harvard negli USA) che, unitamente al Laboratorio Centrale di Genova, sviluppano i programmi di ricerca del piano scientifico 2015-2017.

IIT: the numbers

Istituto Italiano di Tecnologia (IIT) is a public research institute that adopts the organizational model of a private law foundation. IIT is overseen by Ministero dell'Istruzione, dell'Università e della Ricerca and Ministero dell'Economia e delle Finanze (the Italian Ministries of Education, Economy and Finance).  The Institute was set up according to Italian law 326/2003 with the objective of promoting excellence in basic and applied research andfostering Italy’s economic development. Construction of the Laboratories started in 2006 and finished in 2009.

IIT has an overall staff of about 1,440 people. The scientific staff covers about 85% of the total. Out of 45% of researchers coming from abroad 29% are foreigners coming from more than 50 countries and 16% are returned Italians. The scientific staff currently consists of approximately 60 Principal Investigators110 researchers and technologists350 post-docs and 500 PhD students and grant holders and 130 technicians. External funding has allowed the creation of more than 330 positions . The average age is 34 and the gender balance proportion  is 41% female against 59% male.

In 2015 IIT received 96 million euros in public funding (accounting for 80% of its budget) and obtained 22 million euros in external funding (accounting for 20% of its budget). External funding comes from 18 European Projects, other 17 national and international competitive projects and approximately 60 industrial projects.

So far IIT accounts for: about 6990 publications, more than 130 European grants and 11 ERC grants, more than 350 patents or patent applications12 up start-ups and as many  which are about to be launched. The Institute’s scientific activity has been further strengthened since 2009 with the establishment of 11 research nodes throughout Italy (Torino, Milano, Trento, Parma, Roma, Pisa, Napoli, Lecce, Ferrara) and abroad (MIT and Harvard University, USA), which, along with the Genoa-based Central Lab, implement the research programs included in the 2015-2017 Strategic Plan.